Merrimack Pharmaceuticals, Inc.

Bryan Johnson

Alexey Alexandrovich Lugovskoy

Jonathan Basil Fitzgerald

Sharlene Adams

Neeraj Kohli

Lihui Xu

Jason Baum

Provided are monospecific and bispecific antibodies that are useful as anti-neoplastic agents and that bind specifically to human IGF-1R and human ErbB3. Exemplary antibodies inhibit signal transduction through either or both of IGF-1R and ErbB3. Exemplary polyvalent proteins comprise at least one anti-IGF-1R binding site and at least one anti-ErbB3 binding site. In certain embodiments the binding sites may be linked through an immunoglobulin constant region. AntiErbB3 and anti-IGF-1R antibodies (e.g., monoclonal antibodies) are also provided.

Monospecific and bispecific anti-IGF-1R and anti-ErbB3 antibodies

Monospecific and bispecific anti-IGF-1R and anti-ERBB3 antibodies

Provided are bispecific antibodies that are useful as anti-neoplastic agents and that bind specifically to human IGF-1R and human ErbB3. Exemplary antibodies inhibit signal transduction through either or both of IGF-1R and ErbB3.

Bispecific anti-IGF-1R and anti-ErbB3 antibodies

Growing community of inventors

Natick, MA, United States of America

Bryan Johnson